Bisperoxovanadium, a phospho‐tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype
Laura Castaldi(Institut de Myologie), Marina Bouché(Sapienza University of Rome), Mario Molinaro(Sapienza University of Rome), Alessandro Pisaniello(Institut de Myologie), Giulio Cossu(Vita-Salute San Raffaele University), Graziella Messina(University of Milan), R Paoletti, Carlo Serra(Boston University), Massimo Levrero(Northwest Medical Specialties), Marta Baiocchi(Istituto Superiore di Sanità), Alessandro Torgovnick(University of Cologne), Fabrizio Padula(Institut de Myologie), Maurilio Sampaolesi(Sapienza University of Rome), Francesca Moretti(Novartis (Switzerland))
Cited by 19
Related Papers
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
|Cancer Cell|2005|1.3k
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells
|Nature Cell Biology|2007|979
Cell Therapy of α-Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts
|Science|2003|620
Role of Inflammation in Muscle Homeostasis and Myogenesis
|Mediators of Inflammation|2015|535